Angus Liu
Deputy Editor at Fierce Biotech
Deputy Editor at FiercePharma
Biopharma follower @FiercePharma & @FierceBiotech. Medill MSJ 16
Articles
-
2 days ago |
fiercepharma.com | Angus Liu
Bluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers Carlyle and SK Capital to extend their offer deadline once again. Bluebird investors now have until the end of day May 28, U.S. Eastern Daylight Time, to tender their shares, the acquirer group said, according to a bluebird securities filing Tuesday. The offer was previously scheduled to expire on Monday, May 12.
-
3 days ago |
fiercepharma.com | Angus Liu
The HER2-targeted antibody-drug conjugate that Pfizer gained from its Seagen buyout has delivered positive results in a pivotal study among Chinese patients with newly diagnosed bladder cancer, a readout that bodes well for the New York pharma’s own global phase 3 trial.
-
6 days ago |
fiercepharma.com | Ayla Ellison |Angus Liu
Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of Metaphore Biotechnologies. In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma Deputy Editor Angus Liu about her transition from marketing drugs at a Big Pharma company to advancing novel technology at a young biotech startup.
-
6 days ago |
fiercepharma.com | Angus Liu
Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a potential "inflection point" for the company. President Donald Trump is directing the FDA to go hard on foreign manufacturing facilities. And more. 1. AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trialAstraZeneca and Daiichi Sankyo reported a positive readout for Enhertu as a neoadjuvant therapy in early-stage breast cancer.
-
1 week ago |
fiercepharma.com | Angus Liu
The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty Makary, M.D.As head of the FDA’s oncology department, Richard Pazdur, M.D., represents the only FDA center director left from the prior administration. The biopharma industry will be looking eagerly for signs of policy consistency from the upcoming public meeting. The next meeting will take two days on May 20 and 21, according to a Federal Register notice (PDF).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 757
- Tweets
- 107
- DMs Open
- No